Ahmad Chitsaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ahmad Chitsaz has a total of 211 co-authors. Here are the top co-authors by number of shared publications:
- Zamzam Paknahad
Department of Clinical Nutrition, Faculty of Nutrition and Food Science Isfahan University of Medical Sciences Isfahan Iran
8 shared publications - Amir Reza Moravejolahkami
Isfahan University of Medical Sciences
6 shared publications Masoud Etemadifar
Department of Neurology, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
5 shared publications- Akbar Hassanzadeh
Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
3 shared publications Fereshteh Ashtari
Department of Neurology, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran
3 shared publicationsMohammad Saadatnia
Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran
3 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 19 (4) , 398-408
Disease Course, Survival, and Genetic Heterogeneity in Chorea-Acanthocytosis: A Case Series of 34 Patients
Objective To quantify key disease milestones, particularly loss of ambulation and survival, and to describe the VPS13A variant spectrum and clinical heterogeneity in patients with chorea-acanthocytosis (ChA).Methods We conducted a cross-sectional study of 34 ChA patients from 24 unrelated families. Whole-exome sequencing identified VPS13A variants in all probands. Clinical and paraclinical data were collected through neurological evaluations and electronic medical records. Patients were classified as either surviving (ambulatory or non-ambulatory) or deceased.Results Twenty-one VPS13A variants were identified, including 12 novel variants. Median current age and disease duration were 38.5 years (interquartile range [IQR], 34–43 years) and 8.0 years (IQR, 4–12.25 years), respectively. Loss of ambulation occurred in 26.5% of patients after a median of 10 years (range, 5–16 years) from onset. Kaplan–Meier analysis estimated a median time to loss of ambulation of 16.0 years (95% confidence interval [CI], 8.8–23.2 years), with estimated ambulation probabilities of 87.4% at 6 years and 38.0% at 16 years. Seven patients died after a median disease duration of 10 years (range, 3–17 years). The median survival time was not reached during follow-up; the estimated restricted mean survival time was 16.7 years (95% CI, 14.1–19.3 years). Compulsions co-occurred with obsessions in all cases and were associated with higher rates of suicidal ideation, while insomnia was more frequent in patients without compulsions. Suicide and sepsis were the leading causes of death.Conclusion This study defines the natural history of ChA, providing prognostic data on ambulation and survival. The discovery of novel VPS13A variants highlights genetic heterogeneity and supports further investigation into disease mechanisms and therapeutic targets.
- 31 October 2026
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 19 (4) , 398-408
Open AccessDisease Course, Survival, and Genetic Heterogeneity in Chorea-Acanthocytosis: A Case Series of 34 Patients
Objective To quantify key disease milestones, particularly loss of ambulation and survival, and to describe the VPS13A variant spectrum and clinical heterogeneity in patients with chorea-acanthocytosis (ChA).Methods We conducted a cross-sectional study of 34 ChA patients from 24 unrelated families. Whole-exome sequencing identified VPS13A variants in all probands. Clinical and paraclinical data were collected through neurological evaluations and electronic medical records. Patients were classified as either surviving (ambulatory or non-ambulatory) or deceased.Results Twenty-one VPS13A variants were identified, including 12 novel variants. Median current age and disease duration were 38.5 years (interquartile range [IQR], 34–43 years) and 8.0 years (IQR, 4–12.25 years), respectively. Loss of ambulation occurred in 26.5% of patients after a median of 10 years (range, 5–16 years) from onset. Kaplan–Meier analysis estimated a median time to loss of ambulation of 16.0 years (95% confidence interval [CI], 8.8–23.2 years), with estimated ambulation probabilities of 87.4% at 6 years and 38.0% at 16 years. Seven patients died after a median disease duration of 10 years (range, 3–17 years). The median survival time was not reached during follow-up; the estimated restricted mean survival time was 16.7 years (95% CI, 14.1–19.3 years). Compulsions co-occurred with obsessions in all cases and were associated with higher rates of suicidal ideation, while insomnia was more frequent in patients without compulsions. Suicide and sepsis were the leading causes of death.Conclusion This study defines the natural history of ChA, providing prognostic data on ambulation and survival. The discovery of novel VPS13A variants highlights genetic heterogeneity and supports further investigation into disease mechanisms and therapeutic targets.
- 29 June 2025
- Published by Maad Rayan Publishing Company in Journal of Shahrekord University of Medical Sciences
- Vol. 27 (2) , 80-85
Impact of a 12-week combined strength, aerobic, and balance training program on dopamine and serotonin levels in patients with Parkinson’s disease: a randomized clinical trial
Background and aims: Serotonin and dopamine are monoamine neurotransmitters that are reduced in Parkinson’s disease) (PD). This study examined the effects of the 12-week combined strength, aerobic, and balance training program on dopamine and serotonin plasma levels in patients with Parkinson’s disease (PD). Methods: This study was designed as a randomized clinical trial. A total of 30 participants were selected using convenience sampling and randomly assigned to one of two groups using block randomization, including a combined exercise group (strength, aerobic, and balance exercises) of 15 participants and a PD group with 15 participants. The study was conducted in 2024 in Isfahan, Iran. The training program lasted 12 weeks, with five weekly sessions held at a sports club. The data were analyzed using ANCOVA for between-group comparisons and a paired test for within-group changes (P<0.05). Results: The results revealed significant differences in dopamine and serotonin among the two PD groups (P<0.001). However, there was a substantial increase in the combined exercise program group compared with the PD group (P<0.001). In the combined exercise group, dopamine levels increased from 0.0141±0.003 at the pretest to 0.0853±0.033 at the posttest (P=0.001). Finally, serotonin levels rose from 4.59±0.56 to 6.59±0.90 (P=0.001). Conclusion: The combined exercise increased the dopamine and serotonin levels in PD. Accordingly, performing combined exercise can be used as a therapeutic intervention in PD prevention and treatment strategies.
- 29 June 2025
- Published by Maad Rayan Publishing Company in Journal of Shahrekord University of Medical Sciences
- Vol. 27 (2) , 80-85
Impact of a 12-week combined strength, aerobic, and balance training program on dopamine and serotonin levels in patients with Parkinson’s disease: a randomized clinical trial
Background and aims: Serotonin and dopamine are monoamine neurotransmitters that are reduced in Parkinson’s disease) (PD). This study examined the effects of the 12-week combined strength, aerobic, and balance training program on dopamine and serotonin plasma levels in patients with Parkinson’s disease (PD). Methods: This study was designed as a randomized clinical trial. A total of 30 participants were selected using convenience sampling and randomly assigned to one of two groups using block randomization, including a combined exercise group (strength, aerobic, and balance exercises) of 15 participants and a PD group with 15 participants. The study was conducted in 2024 in Isfahan, Iran. The training program lasted 12 weeks, with five weekly sessions held at a sports club. The data were analyzed using ANCOVA for between-group comparisons and a paired test for within-group changes (P<0.05). Results: The results revealed significant differences in dopamine and serotonin among the two PD groups (P<0.001). However, there was a substantial increase in the combined exercise program group compared with the PD group (P<0.001). In the combined exercise group, dopamine levels increased from 0.0141±0.003 at the pretest to 0.0853±0.033 at the posttest (P=0.001). Finally, serotonin levels rose from 4.59±0.56 to 6.59±0.90 (P=0.001). Conclusion: The combined exercise increased the dopamine and serotonin levels in PD. Accordingly, performing combined exercise can be used as a therapeutic intervention in PD prevention and treatment strategies.
- 1 February 2024
- Published by SAGE Publications in Mediterranean Journal of Nutrition and Metabolism
- Vol. 17 (2) , 133-147
Co-supplementation of synbiotics and anti-inflammatory-antioxidant rich diet in patients with progressive forms of multiple sclerosis: A single-center, randomized clinical trial
BACKGROUND: The relationship between dietary modification and Multiple Sclerosis (MS)-related disability has been emphasized in several researches. AIMS: To determine whether a co-administration of anti-inflammatory-antioxidant rich diet and synbiotics might improve clinical manifestations in progressive MS patients. METHODS: The study involved 70 patients with progressive MS (primary-progressive, secondary-progressive, and progressive-relapsing) who were randomized to receive either intervention (synbiotics capsule plus an anti-inflammatory-antioxidant-rich diet) or placebo. Quality of Life (QOL), Expanded Disability Status Scale (EDSS), and depression-anxiety scores were evaluated before and after the follow-up. Analysis of covariance was performed for final analysis (SPSS v.14). RESULTS: Significant reductions were seen in EDSS (2.6±1.1 to 2.4±1.0, P < 0.001), State Anxiety Inventory (53.7±10.3 to 47.8±10.6, P < 0.001), and QOL scores after four months of intervention. No significant difference was seen across the depression severity ( Δ for intervention = –2.2±5.5 vs. Δ for control = –0.6±5.7; P = 0.264). CONCLUSION: This study demonstrates that a combination of synbiotics and diet could be a promising strategy to improve severity and clinical manifestations of progressive MS.
- 1 February 2024
- Published by SAGE Publications in Mediterranean Journal of Nutrition and Metabolism
- Vol. 17 (2) , 133-147
Co-supplementation of synbiotics and anti-inflammatory-antioxidant rich diet in patients with progressive forms of multiple sclerosis: A single-center, randomized clinical trial
BACKGROUND: The relationship between dietary modification and Multiple Sclerosis (MS)-related disability has been emphasized in several researches. AIMS: To determine whether a co-administration of anti-inflammatory-antioxidant rich diet and synbiotics might improve clinical manifestations in progressive MS patients. METHODS: The study involved 70 patients with progressive MS (primary-progressive, secondary-progressive, and progressive-relapsing) who were randomized to receive either intervention (synbiotics capsule plus an anti-inflammatory-antioxidant-rich diet) or placebo. Quality of Life (QOL), Expanded Disability Status Scale (EDSS), and depression-anxiety scores were evaluated before and after the follow-up. Analysis of covariance was performed for final analysis (SPSS v.14). RESULTS: Significant reductions were seen in EDSS (2.6±1.1 to 2.4±1.0, P < 0.001), State Anxiety Inventory (53.7±10.3 to 47.8±10.6, P < 0.001), and QOL scores after four months of intervention. No significant difference was seen across the depression severity ( Δ for intervention = –2.2±5.5 vs. Δ for control = –0.6±5.7; P = 0.264). CONCLUSION: This study demonstrates that a combination of synbiotics and diet could be a promising strategy to improve severity and clinical manifestations of progressive MS.
- 1 December 2023
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 11 (1) , 53-62
Estimation of Ambulation and Survival in Neurodegeneration with Brain Iron Accumulation Disorders
Background: Neurodegeneration with Brain Iron Accumulation (NBIA) disorder is a group of ultra‐orphan hereditary diseases with very limited data on its course.Objectives: To estimate the probability of preserving ambulatory ability and survival in NBIA.Methods: In this study, the electronic records of the demographic data and clinical assessments of NBIA patients from 2012 to 2023 were reviewed. The objectives of the study and factors impacting them were investigated by Kaplan–Meier and Cox regression methods.Results: One hundred and twenty‐two genetically‐confirmed NBIA patients consisting of nine subtypes were enrolled. Twenty‐four and twenty‐five cases were deceased and wheelchair‐bound, with a mean disease duration of 11 ± 6.65 and 9.32 ± 5 years. The probability of preserving ambulation and survival was 42.9% in 9 years and 28.2% in 15 years for classical Pantothenate Kinase‐Associated Neurodegeneration (PKAN, n = 18), 89.4% in 7 years and 84.7% in 9 years for atypical PKAN (n = 39), 23% in 18 years and 67.8% in 14 years for Mitochondrial Membrane Protein‐Associated Neurodegeneration (MPAN, n = 23), 75% in 20 years and 36.5% in 33 years for Kufor Rakeb Syndrome (KRS, n = 17), respectively. The frequencies of rigidity, spasticity, and female gender were significantly higher in deceased cases compared to surviving patients. Spasticity was the only factor associated with death (Pvalue = 0.03).Conclusions: KRS had the best survival with the most extended ambulation period. The classical PKAN and MPAN cases had similar progression patterns to loss of ambulation ability, while MPAN patients had a slower progression to death. Spasticity was revealed to be the most determining factor for death.
- 1 December 2023
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 11 (1) , 53-62
Estimation of Ambulation and Survival in Neurodegeneration with Brain Iron Accumulation Disorders
Background: Neurodegeneration with Brain Iron Accumulation (NBIA) disorder is a group of ultra‐orphan hereditary diseases with very limited data on its course.Objectives: To estimate the probability of preserving ambulatory ability and survival in NBIA.Methods: In this study, the electronic records of the demographic data and clinical assessments of NBIA patients from 2012 to 2023 were reviewed. The objectives of the study and factors impacting them were investigated by Kaplan–Meier and Cox regression methods.Results: One hundred and twenty‐two genetically‐confirmed NBIA patients consisting of nine subtypes were enrolled. Twenty‐four and twenty‐five cases were deceased and wheelchair‐bound, with a mean disease duration of 11 ± 6.65 and 9.32 ± 5 years. The probability of preserving ambulation and survival was 42.9% in 9 years and 28.2% in 15 years for classical Pantothenate Kinase‐Associated Neurodegeneration (PKAN, n = 18), 89.4% in 7 years and 84.7% in 9 years for atypical PKAN (n = 39), 23% in 18 years and 67.8% in 14 years for Mitochondrial Membrane Protein‐Associated Neurodegeneration (MPAN, n = 23), 75% in 20 years and 36.5% in 33 years for Kufor Rakeb Syndrome (KRS, n = 17), respectively. The frequencies of rigidity, spasticity, and female gender were significantly higher in deceased cases compared to surviving patients. Spasticity was the only factor associated with death (Pvalue = 0.03).Conclusions: KRS had the best survival with the most extended ambulation period. The classical PKAN and MPAN cases had similar progression patterns to loss of ambulation ability, while MPAN patients had a slower progression to death. Spasticity was revealed to be the most determining factor for death.
- 26 August 2023
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 27 (10) , 551-559
New Daily Persistent Headache (NDPH): Unraveling the Complexities of Diagnosis, Pathophysiology, and Treatment
Purpose of Review The current article aims to provide an overview of new daily persistent headache (NDPH), with a particular emphasis on its pathophysiology, evaluation, and current treatment options. Recent Findings NDPH is an uncommon and heterogeneous condition associated with various comorbidities and is of great significance due to its prolonged duration and high severity. Variable causes and clinical aspects of NDPH may reflect differences in its underlying pathophysiological mechanisms, including genetics, environmental triggers, neuroinflammation, and brain changes. When assessing a patient with NDPH, potential triggers, past medical history, and differential diagnosis should be carefully considered. Non-pharmacological interventions aimed to improve diet, sleep patterns, and reduce consumption of caffeine and alcohol are recommended for all patients. Nerve blockade and nerve stimulation seem to be more efficacious in children than adults. Antiviral medications and neuroinflammation-targeting treatments may be helpful, particularly, when an infectious disease or severe inflammation is suspected. NDPH patients with concurrent affective disorders may benefit from treatment with serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors, or benzodiazepines. Cerebrospinal-fluid-lowering medications may be useful for headaches started with a thunderclap or a Valsalva maneuver. Possible treatments for refractory NDPH include intravenous ketamine or lidocaine, onabotulinumtoxinA, and calcitonin gene-related peptide antibodies. Summary Considering the variety of NDPH, it is critical to properly screen patients for correct diagnosis. Proper identification of potential mimics may enable precise therapy opportunities, yet there is no gold standard treatment for NDPH. Further well-designed studies are needed to elucidate the underlying mechanisms and develop effective treatment strategies for NDPH.
- 26 August 2023
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 27 (10) , 551-559
New Daily Persistent Headache (NDPH): Unraveling the Complexities of Diagnosis, Pathophysiology, and Treatment
Purpose of Review The current article aims to provide an overview of new daily persistent headache (NDPH), with a particular emphasis on its pathophysiology, evaluation, and current treatment options. Recent Findings NDPH is an uncommon and heterogeneous condition associated with various comorbidities and is of great significance due to its prolonged duration and high severity. Variable causes and clinical aspects of NDPH may reflect differences in its underlying pathophysiological mechanisms, including genetics, environmental triggers, neuroinflammation, and brain changes. When assessing a patient with NDPH, potential triggers, past medical history, and differential diagnosis should be carefully considered. Non-pharmacological interventions aimed to improve diet, sleep patterns, and reduce consumption of caffeine and alcohol are recommended for all patients. Nerve blockade and nerve stimulation seem to be more efficacious in children than adults. Antiviral medications and neuroinflammation-targeting treatments may be helpful, particularly, when an infectious disease or severe inflammation is suspected. NDPH patients with concurrent affective disorders may benefit from treatment with serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors, or benzodiazepines. Cerebrospinal-fluid-lowering medications may be useful for headaches started with a thunderclap or a Valsalva maneuver. Possible treatments for refractory NDPH include intravenous ketamine or lidocaine, onabotulinumtoxinA, and calcitonin gene-related peptide antibodies. Summary Considering the variety of NDPH, it is critical to properly screen patients for correct diagnosis. Proper identification of potential mimics may enable precise therapy opportunities, yet there is no gold standard treatment for NDPH. Further well-designed studies are needed to elucidate the underlying mechanisms and develop effective treatment strategies for NDPH.
- 29 September 2022
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 26 (11) , 1078-1089
Effects of anti-Inflammatory-antioxidant-rich diet and co-supplemented synbiotics intervention in patients with progressive forms of multiple sclerosis: a single-center, single-blind randomized clinical trial
Current evidence has demonstrated that patients with Multiple Sclerosis (MS) have dysbiotic gut microbiomes, and anti-inflammatory nutritional interventions can normalize this status. Therefore, we...
- 29 September 2022
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 26 (11) , 1078-1089
Effects of anti-Inflammatory-antioxidant-rich diet and co-supplemented synbiotics intervention in patients with progressive forms of multiple sclerosis: a single-center, single-blind randomized clinical trial
Current evidence has demonstrated that patients with Multiple Sclerosis (MS) have dysbiotic gut microbiomes, and anti-inflammatory nutritional interventions can normalize this status. Therefore, we...
- Open Access
- 10 September 2022
- Published by Maad Rayan Publishing Company in Hospital Practices and Research
- Vol. 7 (3) , 115-118
Comparing the Efficacy of Amitriptyline and Melatonin on Tinnitus Treatment
Background: Tinnitus is described as the perception of sounds occurring in one or both ears or inside the human head without external auditory stimuli. Objectives: This study aimed to compare the efficacy of amitriptyline and melatonin in the treatment of tinnitus. Methods: This study was a randomized double-blind clinical trial of 60 patients referred to the neurology clinics of Kashani and Al-Zahra hospitals in Isfahan, Iran in 2020. Each patient was randomly assigned 1 code. Patients first filled in the tinnitus handicap inventory (THI) and visual analogue scales (VAS) questionnaires and were given either one of the two drugs (melatonin and amitriptyline) for 6 weeks. After collecting the desired information using an independent t test and paired t test in SPSS 26 software and error level of 0.05 the results were analyzed. Results: Thirty patients were in the amitriptyline group and 30 patients were in the melatonin group, of which 25 were men (41.7%) and 35 were women (58.3%) with a minimum age of 18 years and a maximum of 65 years. There was no significant difference between the reduction of tinnitus before and after taking the drugs based on VAS scale in amitriptyline and melatonin groups (P=0.234), however there was a significant difference between the effect of two amitriptyline and melatonin drugs on the reduction of tinnitus based on the THI questionnaire (P=0.018). Conclusion: The rate of tinnitus in patients decreased for 6 weeks with the use of amitriptyline and melatonin, but amitriptyline had a better effect on reducing the complications and pain of tinnitus.
- 10 September 2022
- Published by Maad Rayan Publishing Company in Hospital Practices and Research
- Vol. 7 (3) , 115-118
Open AccessComparing the Efficacy of Amitriptyline and Melatonin on Tinnitus Treatment
Background: Tinnitus is described as the perception of sounds occurring in one or both ears or inside the human head without external auditory stimuli. Objectives: This study aimed to compare the efficacy of amitriptyline and melatonin in the treatment of tinnitus. Methods: This study was a randomized double-blind clinical trial of 60 patients referred to the neurology clinics of Kashani and Al-Zahra hospitals in Isfahan, Iran in 2020. Each patient was randomly assigned 1 code. Patients first filled in the tinnitus handicap inventory (THI) and visual analogue scales (VAS) questionnaires and were given either one of the two drugs (melatonin and amitriptyline) for 6 weeks. After collecting the desired information using an independent t test and paired t test in SPSS 26 software and error level of 0.05 the results were analyzed. Results: Thirty patients were in the amitriptyline group and 30 patients were in the melatonin group, of which 25 were men (41.7%) and 35 were women (58.3%) with a minimum age of 18 years and a maximum of 65 years. There was no significant difference between the reduction of tinnitus before and after taking the drugs based on VAS scale in amitriptyline and melatonin groups (P=0.234), however there was a significant difference between the effect of two amitriptyline and melatonin drugs on the reduction of tinnitus based on the THI questionnaire (P=0.018). Conclusion: The rate of tinnitus in patients decreased for 6 weeks with the use of amitriptyline and melatonin, but amitriptyline had a better effect on reducing the complications and pain of tinnitus.
- Open Access
- 29 July 2022
- Published by Medknow in Journal of Research in Medical Sciences
- Vol. 27 (1) , 55
Comparison of pramipexole and citalopram in the treatment of depression in Parkinson's disease
Background: Depression is one of the most common neuropsychiatric symptoms in Parkinson's disease (PD). There is little evidence to guide depression treatment in these patients. The aim of this study was to compare citalopram and pramipexole in reducing depressive symptoms in patients with PD. Materials and Methods: In the present 8-week randomized trial, we compared the efficacy of pramipexole versus citalopram in the treatment of depression in PD patients. For this purpose, 44 PD patients with depression randomly received open-label oral citalopram tablets or pramipexole and their depression, quality of life, and daytime sleepiness scores were evaluated at baseline and after the 8-week trial period. Results: The median age of the patients was 64 years, and about 85% of them were male in both groups. The Beck Depression Inventory score, Parkinson's disease summary index (PDSI), and Epworth Sleepiness Scale were significantly decreased (P < 0.05) in both citalopram and pramipexole groups throughout this period and without significant difference (P > 0.05) between these two groups, except for PDSI score which showed significant improvement in pramipexole group compared with citalopram group (P < 0.0001, r = 0.319). There were neither serious adverse effects nor treatment discontinuation due to the adverse effects. Conclusion: The results indicated that both citalopram and pramipexole were effective in the alleviation of depression and improving the quality of life in PD patients; however, pramipexole was seemed to be slightly more beneficial on quality of life in these patients. Therefore, pramipexole seems to be an effective treatment for depression in addition to its benefits for motor symptoms of PD patients.
- 29 July 2022
- Published by Medknow in Journal of Research in Medical Sciences
- Vol. 27 (1) , 55
Open AccessComparison of pramipexole and citalopram in the treatment of depression in Parkinson's disease
Background: Depression is one of the most common neuropsychiatric symptoms in Parkinson's disease (PD). There is little evidence to guide depression treatment in these patients. The aim of this study was to compare citalopram and pramipexole in reducing depressive symptoms in patients with PD. Materials and Methods: In the present 8-week randomized trial, we compared the efficacy of pramipexole versus citalopram in the treatment of depression in PD patients. For this purpose, 44 PD patients with depression randomly received open-label oral citalopram tablets or pramipexole and their depression, quality of life, and daytime sleepiness scores were evaluated at baseline and after the 8-week trial period. Results: The median age of the patients was 64 years, and about 85% of them were male in both groups. The Beck Depression Inventory score, Parkinson's disease summary index (PDSI), and Epworth Sleepiness Scale were significantly decreased (P < 0.05) in both citalopram and pramipexole groups throughout this period and without significant difference (P > 0.05) between these two groups, except for PDSI score which showed significant improvement in pramipexole group compared with citalopram group (P < 0.0001, r = 0.319). There were neither serious adverse effects nor treatment discontinuation due to the adverse effects. Conclusion: The results indicated that both citalopram and pramipexole were effective in the alleviation of depression and improving the quality of life in PD patients; however, pramipexole was seemed to be slightly more beneficial on quality of life in these patients. Therefore, pramipexole seems to be an effective treatment for depression in addition to its benefits for motor symptoms of PD patients.
- Open Access
- 22 June 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (7) , 816
Can Early Neuromuscular Rehabilitation Protocol Improve Disability after a Hemiparetic Stroke? A Pilot Study
Background: The impairment of limb function and disability are among the most im portant consequences of stroke. To date, however, little research has been done on the early reha bilitation trial (ERT) after stroke in these patients. The purpose of this study was to evaluate the impact of ERT neuromuscular protocol on motor function soon after hemiparetic stroke. The sample included twelve hemiparetic patients (54.3 ± 15.4 years old) with ischemic stroke (n = 7 control, n = 5 intervention patients). ERTwas started as early as possible after stroke and included passive range of motion exercises, resistance training, assisted standing up, and active exercises of the healthy side of the body, in addition to encouraging voluntary contraction of affected limbs as much as possible. The rehabilitation was progressive and took 3 months, 6 days per week, 2–3 h per session. Fu gle-Meyer Assessment (FMA), Box and Blocks test (BBT) and Timed up and go (TUG) assessments were conducted. There was a significantly greater improvement in the intervention group com pared to control: FMA lower limbs (p = 0.001), total motor function (p = 0.002), but no significant difference in FMA upper limb between groups (p = 0.51). The analysis of data related to BBT showed no significant differences between the experimental and control groups (p = 0.3). However, TUG test showed significant differences between the experimental and control groups (p = 0.004). The most important finding of this study was to spend enough time in training sessions and provide adequate rest time for each person. Our results showed that ERT was associated with improved motor function but not with the upper limbs. This provides a basis for a definitive trial.
- 22 June 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (7) , 816
Open AccessCan Early Neuromuscular Rehabilitation Protocol Improve Disability after a Hemiparetic Stroke? A Pilot Study
Background: The impairment of limb function and disability are among the most im portant consequences of stroke. To date, however, little research has been done on the early reha bilitation trial (ERT) after stroke in these patients. The purpose of this study was to evaluate the impact of ERT neuromuscular protocol on motor function soon after hemiparetic stroke. The sample included twelve hemiparetic patients (54.3 ± 15.4 years old) with ischemic stroke (n = 7 control, n = 5 intervention patients). ERTwas started as early as possible after stroke and included passive range of motion exercises, resistance training, assisted standing up, and active exercises of the healthy side of the body, in addition to encouraging voluntary contraction of affected limbs as much as possible. The rehabilitation was progressive and took 3 months, 6 days per week, 2–3 h per session. Fu gle-Meyer Assessment (FMA), Box and Blocks test (BBT) and Timed up and go (TUG) assessments were conducted. There was a significantly greater improvement in the intervention group com pared to control: FMA lower limbs (p = 0.001), total motor function (p = 0.002), but no significant difference in FMA upper limb between groups (p = 0.51). The analysis of data related to BBT showed no significant differences between the experimental and control groups (p = 0.3). However, TUG test showed significant differences between the experimental and control groups (p = 0.004). The most important finding of this study was to spend enough time in training sessions and provide adequate rest time for each person. Our results showed that ERT was associated with improved motor function but not with the upper limbs. This provides a basis for a definitive trial.